GlobalData on MSN1mon
Sanofi moves closer to selling controlling stake in $17bn-valued Opellaand irritable bowel syndrome (IBS) relief medicine Buscopan (hyoscine butylbromide), among others. Sales in the business ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback